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Tick-borne encephalitis (TBE) virus is classified as one species with three subtypes, namely 
the European subtype, the Siberian subtype and the Far Eastern subtype. TBE is distributed 
in an endemic pattern of so-called natural foci over a wide geographical area from Western 
Europe to the northern part of Japan. It is the most important flavivirus infection of the 
central nervous system in Europe and Russia, with about 13,000 estimated human cases per 
year. The epidemiology of TBE is closely related to the ecology and biology of ixodid ticks. 
In nature, TBE virus is propagated in a cycle involving permanently infected ticks and wild 
vertebrate hosts. Currently, the diagnosis of TBE is mainly based on the detection of specific 
antibodies in serum and cerebrospinal fluid. No specific treatment for the disease is 
available to date, but it can be prevented by active immunization. 
2. Ecology of TBE virus 
According to the concept of Pavlovskij, TBE virus is maintained in a cycle involving ticks 
and wild vertebrate animals in forested natural foci under certain botanical, zoological, 
climatical and geo-ecological conditions (Pavlovskij, 1939). The development of a TBE 
natural focus depends on the coincidence of all these factors.   
The principal carrier (vector) as well as the reservoir of the European TBE virus subtype is 
the tick Ixodes ricinus (Rampas and Gallia, 1949), a dominant hard tick across Europe. 
However, the virus has been isolated also from several other tick species (Grešíková and 
Nosek, 1966; Křivanec et al., 1988; Grešíková and Kaluzová, 1997). I. ricinus ticks live 
preferentially in the dense undergrowth of the forests where the relative humidity is high. 
Oak, hornbeam as well as beech and fir woods with rich undergrowth of weeds, ferns, elder, 





TBE virus strains from Far Eastern and Siberian subtypes are transmitted predominantly by 
I. persulcatus. This tick, which aggressively attaches to humans, comprises 80–97% of all tick 
species in the Ural, Siberia and the Far East region of Russia (Gritsun et al., 2003a). The 
habitat of I. persulcatus is mainly distributed in different taiga forest types. Key factors 
affecting I. persulcatus ticks are relatively warm and humid climate conditions. In the event 
of high humidity the ticks are frequent in warm and drained spruce and small-leaved 
forests. Under low humidity and warm conditions, the ticks are frequent in broad-leaved 
coniferous forests and in shaded places. The natural (boreal) habitat of I. persulcatus ticks 
spreads from the Baltic States to the Pacific. On the border of habitats (Baltic States, Finland, 
Karelia, and several regions of the European part of Russia) sympatric habitations of I. 
persulcatus and I. ricinus were observed (Votiakov et al., 2002).  
The TBE natural foci do not expand beyond the natural habitats. However, TBE virus has 
been isolated also from 18 other tick species in Russia (e.g. frequently from Dermacentor 
marginatus in some steppe regions), but sporadically also from other parasitic invertebrates, 
e.g. fly, flea and lice (Gritsun et al., 2003b).  
The life cycle of ticks (Fig. 1) consists of three stages: the larva, nymph and adult. Each stage 
feeds on a different individual vertebrate host, usually for a period of a few days. E.g., the 
infection rate of fed adult ticks and their immediate progenies depends on the bigger 
mammalian hosts: cattle and wild hares, foxes, boars and deer. Therefore, these hosts are of 
primary importance for the existence and transmission of TBE virus.    
Each stage of I. ricinus takes approximately one year to develop to the next stage. Thus, the 
shortest life cycle takes 3 years on average to complete. However, it may vary from 2 to 6 
years throughout the geographical range, depending on the availability of hosts and climatic 
conditions (Süss, 2003). Following copulation, the female spends six to eleven days feeding 
on blood and, during subsequent months, deposits 500 to 5,000 eggs. Several weeks later, 
larvae measuring 0.6–1.0 mm hatch from the eggs. The molting occurs only twice. Six-legged 
larva develops into an eightlegged nymph, which in turn molts to produce a similar but 
larger adult (Süss, 2003). TBE virus can be transmitted to man or other hosts by all the tick 
stages, i.e. larvae, nymphs, as well as adult ticks. 
The virus infects ticks chronically for the duration of their life. Nevertheless, ticks 
themselves do not develop the disease. The virus is transmitted from one developmental 
stage of the tick to the next (transstadial transmission). In the period that precedes molting, 
the virus multiplies in the tick and invades almost all the tick’s organs (Benda, 1958). TBE 
virus can be also transmitted transovarially (from infected fertilized female to egg) (Benda, 
1958) and during co-feeding of ticks on the same host (Labuda et al., 1993; 1997). Despite the 
fact that the percentage of transovarial transmission of members of the European TBE virus 
subtype in I. ricinus is much lower than of Siberian and Far Eastern strains in I. persulcatus, it 
is sufficient under certain conditions to ensure the continuity of virus population. Co-
feeding of both infected and naïve ticks on the same host allows TBE virus transmission 
even in the absence of systemic viremia. Results from laboratory experiments suggested that 
in this case viremia could be a product, rather than a prerequisite, of TBE virus transmission 
(Labuda et al., 1997). Frequently, it is observed that different stages of ticks belonging to 
various generations feed on the same host. Therefore, the virus is transmitted efficiently 
between generations of carriers for at least 5 consecutive years (Korenberg et al., 1991).  
The prevalence of TBE virus infected I. ricinus ticks varies from 0.5% to 5%, whereas in I. 
persulcatus in certain regions of Russia prevalence up to 40% was recorded (Charrel et al., 
2004).  
 





Fig. 1. Life cycle of ixodid tick and transmission cycle of TBE virus. Black lines show the 
cycle of ticks with different developmental stages. At each stage, a blood meal is needed to 
develop into the next stage. Therefore, each tick stage feeds on suitable hosts. Further, adult 
female ticks need a blood meal for egg production. Grey lines show the possible 
transmission of TBE virus. Thickness of grey arrows shows the most probable routes 
Horizontal TBE virus transmission between ticks and their vertebrate reservoir hosts is 
necessary for virus endemism (Fig. 1) (Nuttall and Labuda, 2003). The duration of viremia in 
hosts is crucial for TBE virus transmission to ticks, because the virus is mostly ingested by 
ticks just while engorging on a viremic host. Generally, the hosts are divided into three 
groups: reservoir, indicator, and accidental hosts. Natural reservoir hosts of TBE virus, i.e. 
animals that are sensitive to the virus, exhibiting viremia for long period of time without 
becoming clinically ill and thus important for the transmission of the virus to ticks, include 
rodents (Clethrionomys, Apodemus, Mus, Microtus, Micromys, Pitymys, Arvicola, Glis, Sciurus 
and Citellus) (Kožuch et al., 1967), insectivores (Sorex, Talpa, Erinaceus) (Kožuch et al., 1967) 
and carnivores (Vulpes, Mustela) (Süss, 2003; Karabatsos, 1985). Insectivores and rodents 
harbor the virus also during the winter. The long-lasting viremia can be restored after the 
awakening of the animals after the winter sleep (posthibernation viremia). Indicator hosts 
have only brief viremia with low virus production and are not able to transmit the virus to 
vectors.  
Humans are accidental hosts of TBE virus, i.e. they can develop a disease with viremia, but 
they do not participate in virus circulation in nature and are, therefore, a dead end of the 





People can be infected (i) by a bite of an infected tick, (ii) by drinking infected unboiled milk, 
or (iii) by inhaling infected aerosol or by needle-stick injury. In general, most frequently TBE 
virus infection of humans occurs following the bite of an infected tick, which is unnoticed in 
about a third of cases (Kaiser, 1999). The tick usually attaches itself to man while walking in 
dense vegetation in forests. The virus is transmitted by saliva during first minutes of 
feeding. On humans, ticks prefer to attach themselves to the hair-covered portion of the 
head, to the arm and knee bends, hand, feet and ears as well as the gluteal and genital 
regions. In children, 75% of ticks are situated on the head as children are closer to vegetation 
than adults (Süss, 2003). The incidence of human TBE cases correlates with the activity of the 
ticks. The seasonal activity of I. ricinus has two peaks: April–May and September–October. 
Comparison of the tick population curves and the morbidity rate in humans shows that 
there is approximately 14 days’ difference between the peaks of the two curves. The gap 
between the peak of tick activity and the highest morbidity rate in humans corresponds to 
the incubation period of the disease that is between 4 and 14 days. The activity of I. 
persulcatus has only one peak and lasts from the end of April to the beginning of June. 
During July only some sporadic cases can be seen. When the summer is very hot, sporadic 
cases can be observed even in September, but not later (Grešíková and Kaluzová, 1997). The 
duration of epidemic season in the Southern Far East is 6 to 7 months, since imago molt 
from nymphs become active at once (Leonova et al., 1996).  
Another natural route of human TBE virus infection is associated with the consumption of 
nonpasteurized milk from viremic livestock (goats, sheep and cows). The virus can pass 
from the blood of the livestock into the mammary gland. Experiments and epidemiological 
studies have revealed that antibodies to TBE virus are readily eliminated, and one and the 
same goat may be repeatedly infected and may excrete TBE virus with its milk (Korenberg, 
1976). If a human drinks unboiled milk from infected animals, it can lead to the development 
of a form of biphasic meningoencephalitis, called ‘biphasic milk fever’. The virus remains 
stable for a relative long period also in various milk products such as yoghurt, cheese and 
butter (Grešíková, 1959). Persistent infectivity in gastric juice is observed after ingestion of 
such products for up to 2 h (Charrel et al., 2004). With the aim to decrease the risk of TBE 
infection in humans by alimentary route, a candidate life attenuated TBE virus vaccine for 
goats was developed (Mayer, 1966). However, recent molecular analysis of the vaccine strain 
revealed that this vaccination strain is not an attenuated variant of TBE virus, but a strain of 
virus Langat, possibly a result of laboratory contamination of cell cultures (Růžek et al., 2006).  
Single cases of laboratory TBE virus infections from needle-stick injuries or associated with 
aerosol infection of laboratory personnel were also described (Gallia et al., 1949; Molnár and 
Fornosi, 1952; Hoffmann, 1973; Bodemann et al., 1977; Avšič-Županc et al., 1995). 
3. Geographical distribution 
TBE occurs in many parts of Central Europe and Scandinavia, particularly, in Austria, Czech 
Republic, Estonia, Finland, Germany, Hungary, Latvia, Lithuania, Poland, Russia, Slovak 
Republic, Slovenia, Sweden, Switzerland, and also Northern Asia (Fig. 2) (Donoso Mantke et 
al., 2008; Süss, 2008; Lu et al., 2008). Recently, probable TBE cases were described in Turkey 
(Ergünay et al., 2011). Further, new TBE foci are emerging and latent ones re-emerging in a 
number of other European countries (Bröker and Gniel, 2003; Petri et al. 2010). In Russia, the 
highest TBE incidence is reported in Western Siberia and Ural (Grešíková and Kaluzová, 
1997). No TBE cases have been reported e.g. in Great Britain, Ireland, Iceland, Belgium, the 
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Netherlands, Luxemburg, Spain and Portugal. Whereas Bulgaria, Croatia, Denmark, France, 
Greece, Italy, Norway, Romania, Serbia, China and Japan are countries with only sporadic 
TBE occurrence. Because of the increased mobility of people travelling to the risk areas, TBE 
has become an international public health problem with relation to travel medicine. The risk 
of an infection is especially high for people living in endemic areas or visiting them for 
leisure activities in nature (Bröker and Gniel, 2003).  
Although TBE virus is a growing concern in Europe, surveillance and notification schemes 
are not uniform within the European countries. There is a lack of Europe-wide standard case 
definition and the quality of national surveillance programs differs considerably. Therefore, 
surveillance data from different countries are difficult to compare (Donoso Mantke et al., 
2008).  
Generally, the distribution of TBE virus correlates with ixodid tick vectors. I. ricinus occurs 
in most parts of Europe, and the distribution extends to the southeast (Turkey, Northern 
Iran, and Caucasus). I. persulcatus is seen in the wide area extending from Eastern Europe to 
China and Japan. Parallel occurrence of both tick species was reported in North-Eastern 
Europe and the east of Estonia and Latvia as well as in several European regions of Russia 
(Bormane et al., 2004; Golovljova et al., 2004).   
 
 
Fig. 2. Geographical distribution of TBE. 
(http://www.traveldoctor.info/files/disease/10__ImageFile__KrxuNAAeGEcvwVLPnxks
U.gif; date of access April 11, 2011) 
The increase of TBE virus incidence in most European countries during the last decades is 
due to a complex interrelation of several factors that include ecological (effect of climate 
change on the vectors), agricultural, social (changes in human leisure activities), as well as 
technological factors (advanced diagnostics and increased medical awareness) (Donoso 
Mantke et al., 2008). It has been reported that there is an increase (i) in the number of cases 
in areas well known for TBE in humans; (ii) a reemergence of TBE in areas where it had 
previously occurred but had not or only sporadically been observed since the 1970s, or (iii) 





upper limit of the geographical habitats of ticks to higher altitudes was observed in Central 
Europe and Sweden (Daniel et al., 2003). Previously, the limit of ticks’ occurrence was at 
700–750 m above sea level and ticks were not able to finish their developmental cycle at 
higher altitudes. However, recent studies have shown that ticks (including TBE virus 
infected ones) shifted to the altitudes up to 1,000 m above sea level. This shift is in a clear 
correlation with an increased average temperature since the numbers of game animals, 
socio-economical factors or land-usage did not change in these areas (Danielová et al., 2008). 
Since these mountain zones are often used for recreation and outdoor activities, the risk of 
TBE virus infections in these areas increased considerably (Daniel et al., 2003).  
4. Clinical picture 
Serological surveys suggest that 70–95% of human TBE virus infections are either sub-
clinical or asymptomatic (Shapoval, 1976, 1977; Pogodina et al., 1979).  
While courses and symptoms are quite similar in the early stage of disease, TBE caused by 
viruses of the different subtypes may vary not only in the frequency of development of 
certain disease forms (febrile, meningeal, meningoencephalitic, polyencephalitic, 
poliomyelitic, polioradiculoneuritic, and chronic forms), but also in the severity of each 
form.  
Siberian and Far Eastern TBE virus subtypes can be the cause of chronic disease (Pogodina 
et al., 2004; Voronkova and Zakharycheva, 2007). For the Far Eastern TBE virus subtype, the 
frequency of focal encephalitic symptoms is 31–64%, meningeal forms amount to nearly 
26%, febrile forms 14–16% and biphasic forms 3–8%. Complete recovery occurs in 25% of all 
cases (Votiakov et al., 2002). The current increase in the proportion of patients with a febrile 
form is likely to be associated with the improved diagnostics. Case fatality rate is up to 35% 
(Dumpis et al., 1999). Chronic disease develops in less than 0.5% of cases.   
The Siberian subtype is associated with focal encephalitic forms in 5% incidents, meningeal 
forms nearly 47%, febrile forms 40% and biphasic forms about 21%. Complete recovery 
occurs in 80% of all cases. Case fatality rate is nearly 2% (Votiakov et al., 2002). Nevertheless, 
infections with the Siberian subtype have a tendency for patients to develop chronic or 
extremely prolonged infections accompanied by diverse neurological and/or 
neuropsychiatric symptoms (Poponnikova, 2006).   
However, due to differences in seroprevalence rates in Europe and in Russia, the higher 
morbidity of Eastern TBE forms could, at least partly, be the result of selective notification of 
mainly severe cases (Süss, 2003).  
In contrast to the forms mentioned above, infections caused by European strains typically 
take a biphasic course in 72–87% of patients (Kaiser, 1999; Günther et al., 1997; Holzmann, 
2003): After a short incubation period (usually 7–14 days, with extremes of 4–28 days), the 
first (viremic) phase presents as an uncharacteristic influenza-like illness lasting 2–4 days 
(range 1–8 days) with fever, malaise, headache, myalgia, gastrointestinal symptoms, 
leukocytopenia, thrombocytopenia and elevated liver enzymes as frequent symptoms. This 
is often followed by a symptom-free interval of about one week (range 1–33 days) before the 
second phase. Seroconversion without prominent morbidity is common.   
The second phase of TBE occurs in 20–30% of infected patients (Gustaffson et al., 1992) and 
is marked by four clinical features of different severity (meningitis, meningoencephalitis, 
meningoencephalomyelitis or meningoencephaloradiculitis) and the appearance of specific 
antibodies in the serum and cerebrospinal fluid (CSF). This is usually the time when patients 
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with high fever and severe headache seek medical advice. Neurological symptoms at this 
stage principally do not differ from other forms of acute viral meningoencephalitis 
(Lindquist and Vapalathi, 2008).   
The fatality rate in adult patients is less than 2%. However, severe courses of TBE infection 
with higher mortality and long-lasting sequelae often affecting the patient’s quality of life 
have been correlated with increased age (Lindquist and Vapalathi, 2008; Mickiene et al., 
2002). Further factors associated with severe forms are severity of illness in the viremic 
phase and low neutralizing antibody titers at onset of disease (Kaiser and Holzmann, 
2000). 
5. Outbreaks history 
Although the first hints of the existence of TBE date back to Scandinavian church records 
from the 18th century (Åland islands, Finland), the first medical description of the disease 
was given by the Austrian physician H. Schneider in 1931 (Schneider, 1931).   
In 1937–39, the Russian Ministry of Health organized three successive expeditions to the Far 
East with the purpose to elucidate the origin of severe infections of the central nervous 
system (CNS), called ‘taiga encephalitis’ or ‘biphasic meningoencephalitis’, a disease that 
had been observed there since 1914, but more frequently occurred since 1933. Initially, the 
disease was misdiagnosed as a toxic form of influenza. The expeditions revealed viral origin 
of the disease and the tick I. persulcatus as the main vector of the virus (Zilber, 1939). The 
newly described disease was called ‘Russian spring-summer encephalitis’ (or Far East or 
taiga encephalitis). The virus became known as Russian spring-summer encephalitis virus 
and lately tick-borne encephalitis virus. After TBE virus strains were isolated, the clinical 
picture and human pathology aspects were described, and in 1940 the first vaccine was 
tested.  
In the Ural, cases of Kozhevnikov’s epilepsy (epilepsia corticalis sive partialis continua; for 
details see Vein and van Emde Boas, 2011), a supposed complication of TBE that develops 
after acute meningoencephalitis, were described by V.P. Pervushin in 1901 and by M.G. 
Polykovsky in 1917– 1920 (Votiakov et al., 2002). There, TBE virus was isolated for the first 
time from the brain of a deceased patient in 1939 by M.P. Chumakov and N.A. Zeitlenok 
(1940). The history of the discovery of TBE virus in the European part of Russia started with 
the investigation of a TBE outbreak in the Volkhov Front’s armies in 1942–1943. In the same 
period, the role of I. ricinus for virus transmission was demonstrated (Petrishcheva and 
Levkovich, 1945), and TBE virus of the Siberian subtype was isolated from this tick 
(Pogodina et al., 2004). In 1946, an expedition headed by L. Zilber isolated TBE virus from I. 
ricinus ticks and from patients in Belarus. This virus was proved to be in close relationship 
with the then known Louping ill virus rather than with the Far Eastern TBE virus strains. 
Lately, the virus was named the ‘Western tick-borne encephalitis virus’.   
In Central Europe, TBE virus was first isolated from human patients in Czechoslovakia after 
the Second World War in 1948 (Gallia et al., 1949; Krejčí, 1949a) when the incidence of 
clinical manifestations caused by the virus was so high that it was noticed by infectiologists 
in affected regions (Krejčí, 1949b). Simultaneously, the virus was also isolated from  I. ricinus 
suggesting the role of the tick as a vector of the disease (Rampas and Gallia, 1949).  
Retrospective analysis, however, revealed the presence of a clinically similar disease not 
only in Czechoslovakia, but also in a number of other European countries for several 





observed and described the disease without knowing the etiology (reviewed by Izbický, 
1954). In Czechoslovakia, this disease was previously known as ‘Encephalitis epidemica’. Since 
1945, there was nearly a tenfold increase in the incidence of this disease (Izbický, 1954).  
Shortly, after the description of TBE in Czechoslovakia, the virus was isolated in Hungary 
(Fornosi and Molnár, 1952), Poland (Szajna, 1954), Bulgaria (Vaptsarov et al., 1954), 
Yugoslavia (Bedjanič et al., 1955), Austria (Pattyn and Wyler, 1955), Romania (Draganescu, 
1959), Germany (Sinnecker, 1960), but also in Finland (Oker-Blom, 1956) and Sweden 
(Kaäriainen et al., 1961). Simultaneously, the virus was also revealed in Northern China and 
Japan (Ando et al., 1952). Recently, a successful detection of TBE virus in South Korea was 
reported (Kim et al., 2009; Ko et al., 2010).   
The clinical course of the disease, its pathology and epidemiology, as well as the properties 
of the virus, its ecology, and ecology of the vectors have been studied in detail. Most of the 
studies were carried out in Russia, Czechoslovakia and Austria (Kunz and Heinz, 2003).   
The incidence of TBE varies from year to year in different geographic regions. Across 
Eurasia, more than 13,000 human cases are reported annually. Over the last two decades, the 
most dramatic changes of all were the sudden increases (2- to 30-fold) in 1992–3 in Latvia, 
Lithuania, Poland and Belarus, and with marked but lesser increases in Estonia, Germany, 
Slovakia, and the Czech Republic. TBE cases have increased steadily since the mid-1970s in 
Russia, and since the mid-1980s in Switzerland, Sweden, and Finland. In Austria, the only 
country with extensive systematic vaccination coverage, TBE incidence has decreased 
progressively since the early 1980s (Randolph, 2002).  
Russia is the country with the largest geographical range of TBE virus and the highest TBE 
incidence. In the early period of descriptive TBE studies in the 1930s-1940s, 200 cases were 
reported annually in average (with some divergences in 1941 and 1942). The analysis of data 
collected since 1948 demonstrates a registered shift in 1948 followed by a peak in 1956 (5,163 
cases), and by a relative plateau thereafter (3,500 cases per year in average), with the next 
peak in 1964 (5,204 cases). From 1964 to 1974, the incidence dropped to 1,119 cases per year. 
The year 1975 brought a new shift that lasted till 1999 with peaks in 1993 (7,250 cases), 1996 
(10,298 cases), and 1999 (9,955 cases). In some regions, the incidence rate reached 70 per 
100,000 inhabitants. A negative trend in the incidence has been observed since 2000, with 
2,796 cases reported in 2008. Since 2000, the average incidence showed a two-time decrease. 
It should be noted that at the same time the registered trends are of opposite direction. In 
the extreme north-west region of Russian TBE habitats, from 1997 to 2007 a continuous 
positive trend was observed. In Karelia and Vologda regions, the incidence increased twice, 
and in the neighboring Arkhangelsk region increased five times. But since most of the cases 
in Russia are reported for Ural, Siberia and some Volga regions, the data for the north-west 
region has not material impact on the incidence rate in the country as a whole. The data on 
TBE incidences for Russia are based on the reports of the Federal Center of Hygiene and 
Epidemiology in Moscow.  
In Europe, the Czech Republic ranks among the countries with the highest incidence rate of 
TBE. In this country, the incidence of the illness noticeably varied during the monitored 
period, i.e. since 1950s. The high occurrence of the infection in 1960s gradually decreased 
and in 1970s and 1980s reached values of 139–400 cases annually. Sporadically, there were 
more than 400 cases per year in 1970, 1973, and 1979. A steep increase took place in 1990s 
(according to data from EPIDAT, National Institute of Public Health in Prague – 
www.szu.cz), when the annual incidence was more than two-fold higher in comparison 
with the preceding period, 400–600 cases per year with a maximum of 745 cases in 1995 and 
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706 in 2000 (Daniel et al., 2004). In the year 2006, the incidence (1,026 cases) of TBE in the Czech 
Republic was almost twice as high than in the preceding years, the highest ever recorded, 
indicating significantly increased epidemic activity of this important human pathogen (Daniel 
et al., 2008). A similar increase in number of cases was observed also in other regions of 
Europe (www.isw-tbe.info). This phenomenon is not definitely explained. One hypothesis 
dealing with the increased incidence of the last years is based on impact of climatic changes on 
the biology of the vector I. ricinus (Gray et al., 2009). Gradual raise of the temperature in the 
last decades caused prolongation of the period of the tick development within a year and, 
subsequently, acceleration of its development and increase of the density of its population 
(Daniel et al., 2004). This allowed the intensification of the circulation of TBE virus, more 
frequent contact of man with infected ticks, and caused dissemination of the ticks and TBE to 
regions with no or rare previous records of their incidence (Daniel et al., 2003, 2006).   
A particularly unusual outbreak was caused by infected goat milk in the Rožňava district of 
Slovakia in 1951–52, when at least 660 people became infected (Blaškovič, 1954; Růžek et al., 
2010). Other milk-borne TBE virus outbreaks occurred in Petersburg and Moscow regions 
(Drozdov, 1959) in Russia and in the Styrian region of Austria (Grešíková and Kaluzová, 
1994). More recently, a relatively small outbreak of TBE by alimentary route was reported in 
1999 in the Czech Republic. In this case, 22 people were infected by consumption of sheep 
cheese. Some of the cases were severe (Daneš, 2000). In 2007, outbreak of alimentary TBE 
after consumption of unpasteurized raw goat milk involving 25 patients of 154 exposed 
persons occurred in Hungary in August 2007 (Balogh et al., 2010). Lastly, an outbreak of 
TBE due to consumption of goat cheese from an alpine pasture of high altitude (1564 m 
above sea level) was reported in 2008 from an area in Vorarlberg, Austria, in which 6 
persons were infected. Four of them were hospitalized with typical TBE symptoms, 2 were 
clinically asymptomatic (Holzmann et al., 2009). 
6. Virology 
TBE virus is the medically most important member of the tick-borne group of the genus 
Flavivirus, family Flaviviridae (Thiel et al., 2005). Besides TBE virus, three other tick-borne 
flaviviruses, i.e. Louping ill virus, Langat virus and Powassan virus, also cause encephalitis 
in humans and/or animals, but these infections are infrequent and the viruses do not 
produce significant outbreaks (Gritsun et al., 2003b).    
TBE virus is subdivided into three subtypes: European (previously Central European 
encephalitis), Far Eastern (previously Russian spring and summer encephalitis) and Siberian 
(previously Western Siberian encephalitis) (Ecker et al., 1999).   
Based on the antigenic similarity, the European TBE virus subtype is closely related rather to 
Louping ill virus than to the Far Eastern and Siberian subtypes (Hubálek et al., 1995). 
Moreover, on the basis of the comparison of genetic similarity of complete genomes, 
inclusion of Louping ill virus, Turkish sheep tick-borne encephalitis virus, and Spanish 
sheep encephalitis virus as different genotypes of TBE virus was proposed (Grard et al., 
2007), but this classification has not been generally accepted so far, mostly because of 
important biological differences between these viruses.  
Although TBE virus strains isolated from field collected ticks exhibit high heterogeneity 
with respect to their biological properties (Růžek et al., 2008), sequence analyses of various 
virus isolates have shown that the TBE virus is fairly homogeneous in endemic areas of 





of TBE virus from Siberian and Far Eastern subtypes is much higher. Currently, at least two 
groups in the Siberian genotype were identified (European and Asian groups, separated by 
Ural mountains) (Pogodina et al., 2007). Nevertheless, the antigenic similarity is still high 
enough to be sufficient for the cross-protection in the event of infection by TBE virus of the 
different subtypes.  
The virions of TBE virus are spherical particles, approximately 50–60 nm in diameter (Slávik 
et al., 1967) with a nucleocapsid composed of a (+)ssRNA genome enclosed in a capsid (C) 
protein and surrounded by a host cell-derived lipid bilayer. The genome is approximately 
11 kb in length and contains one large open reading frame which is flanked by 5’ and 3’ 
untranslated regions, with 5’-cap but no 3’-poly(A) tail. The untranslated regions form 
conserved secondary stem-loop structures that probably serve as cis-acting elements for 
genome amplification, translation and packaging (Gritsun et al., 2003b). Translation yields a 
3414 amino acids long polyprotein that is co- and post-translationally cleaved by cellular 
and viral proteases into three structural proteins (C, prM, E) and seven non-structural 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). The lipid envelope carries two 
surface proteins, the large envelope protein (E) and a small membrane protein (M). M 
protein is derived from its larger precursor, prM.   
C protein binds viral DNA to form the virion nucleocapsid. The immature C protein contains a 
CTHD (C-terminal hydrophobic domain), i.e. a 20 amino acid length polypeptide, which is 
split off by serine protease to form a short CTHD polypeptide during polyprotein processing 
(Yamshchikov and Compans, 1993). The proteolysis site modification in this region is likely to 
predetermine the maturity rate of virions in the infected cells (Loktev et al., 2007).   
The E protein is the major antigenic and virulence determinant of TBE virus and acts both as 
the ligand to the cell receptor and as the fusion protein (Lindenbach and Rice, 2003).   
The viral non-structural proteins have several functions, i.e. the NS1 protein soluble 
homodimer is known as a complement-binding antigen; NS2A, NS4A and NS4B proteins 
are involved in the function as a replicative complex (Loktev et al., 2007); the complex of 
NS2B-NS3 proteins serves as viral serine protease; and NS5 is a RNA-dependent RNA 
polymerase (Lindenbach and Rice, 2003).   
The infection of the host cell begins with the binding of the virus to a cell receptor, which 
has not been sufficiently identified till now (Kopecký et al., 1999). Apparently, just the 
ability to use multiple receptors can be responsible for the very wide host range of 
flaviviruses, which replicate in arthropods and in a broad range of vertebrates. After 
binding to the receptor, the virus is internalized by endocytosis. Acidification of the interior 
of the endosomal vesicle changes the conformation of the E protein and rearranges its 
dimers to trimeric forms. These changes result in fusion of the viral envelope and the 
membrane of the endosomal vesicle (Holzmann et al., 1995) and the release of the viral 
nucleocapsid into the cytoplasm. After uncoating, translation of the positive-stranded genome 
occurs, in parallel to synthesis of minus-strand RNA that serves as a template for RNA 
replication. Processing of the polyprotein yields the individual viral proteins (Mandl, 2005).  
In vertebrate cells, virus assembly takes place in endoplasmatic reticulum and leads to 
formation of immature virions that contain the proteins C, prM and E. These immature 
particles are transported through the cellular secretory pathway and, shortly before release, 
prM is cleaved by furin or a similar enzyme in the acidic compartment of the trans-Golgi 
network to yield mature and fully infectious virions (Mandl, 2005).   
However, the TBE virus maturation process in tick cells is completely different than in the 
cells from vertebrate hosts. In cell lines derived from the tick Rhipicephalus appendiculatus 
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infected with TBE virus, nucleocapsids occur in cytoplasm and the envelope is acquired by 
budding on cytoplasmic membrane or into cell vacuoles (Šenigl et al., 2006). The studies 
focused on the adaptation of TBE virus to Hyalomma marginatum ticks and mammals 
described the presence of respective adaptive mutations within the second domain of E 
protein (Romanova et al., 2007).  
Most of the studies on TBE pathogenesis have been done on laboratory mice that are 
susceptible to TBE virus and develop lethal infection of CNS (Simon et al., 1966), analogous 
to severe cases of TBE in humans (Mandl, 2005).   
After the tick bite, the virus replicates in subcutaneous tissues (Fig. 3). Dendritic cells in the 
skin are likely to serve as a vehicle for the transport of the virus to draining lymph nodes 
(Labuda et al., 1996). The lymph nodes play an important part in the pathogenesis of TBE. 
However, virus replication is not accompanied by any virus-specific histological changes 
including any destruction of cells in the nodes (Málková and Filip, 1968). On the model of 
Syrian hamsters inoculated intracerebrally with TBE virus strains differing in virulence, 
specific involvement of the organs of the immune system (spleen, lymph nodes, and 
thymus) was established and morphological features of the process described. The most 
severe destructive changes of these organs (mass disintegration of lymphocytes, inhibition 
of their migration, almost complete inhibition of regeneration processes up to the complete 
elimination of germinal centers) were found in the hamsters inoculated with highly virulent 
strains (Karmysheva and Pogodina, 1990). TBE virus can be isolated from blood leucocytes 
during the first days after the tick bite indicating virus replication in immunocompetent 
blood cells (Leonova and Maistrovskaya, 1996).  
 
 
Fig. 3. Schematic drawing of the steps during TBE virus infection. (1) TBE virus transmission 
from an infected tick, (2) TBE virus replication in regional lymph node, (3) primary viremia, 
(4) replication of the virus in other organs and tissues, (5) secondary viremia, (6) TBE virus 





Massive viral multiplication in the nodes leads to the spreading of virus into the blood 
stream and induction of viremia (Málková et al., 1969). Temporary leukopenia in the white 
blood picture is observed. A significant decrease is recorded in all cellular elements. In 
regional lymph nodes, a significant decrease in lymphocytes appears (Málková et al., 1961). 
Many extraneural tissues are infected during the viremic phase and, subsequently during 
the secondary viremia, the virus invades the CNS by still unknown mechanism. Mice dying 
due TBE exhibite severe systemic stress response, and increased levels of TNF-alpha 
compared with recovering mice (Hayasaka et al., 2009). Characteristic, but not disease-
specific, are neuropathologic changes in CNS that include meningitis and 
polioencephalomyelitis accentuated in spinal cord, brainstem and cerebellum associated 
with inflammatory cell infiltration of infected animals (Gelpi et al., 2005). In mice, as well as 
in human post-mortem cases, prominent inflammatory infiltrates and cytotoxic T-cells were 
observed in close contact with morphologically intact neurons suggesting a key role for 
cytotoxic T-cells in the development of encephalitis (Gelpi et al., 2006; Růžek et al., 2009). 
Recent studies confirmed, that the host CD8+ T-lymphocytes infiltrating brain parenchyma 
mediate immunopathology in TBE (Růžek et al., 2009). Thus, the host immune system 
contributes significantly to the development and higher severity of the disease. 
TBE virus infection, in addition to causing fatal encephalitis in mice, induces considerable 
breakdown of the blood-brain barrier (BBB). The permeability of the BBB increases at later 
stages of TBE infection when high virus load is present in the brain (i.e., BBB breakdown 
was not necessary for TBE virus entry into the brain), and at the onset of the first severe 
clinical symptoms of the disease. The increased BBB permeability is in association with 
dramatic upregulation of proinflammatory cytokine/chemokine mRNA expression in the 
brain. Breakdown of the BBB can be also observed in mice deficient in CD8+ T-cells, 
indicating, that these cells are not necessary for the increase in BBB permeability that occurs 
during TBE (Růžek et al., 2011). 
7. Laboratory diagnosis 
Since TBE shows clinical and laboratory findings similar to other CNS diseases which may 
require special treatment, microbiological laboratories have to perform specific diagnostics 
mainly for differential diagnosis (Donoso Mantke et al., 2007a).  
This can be done (i) as direct detection of the virus or viral RNA in the first (viremic) phase 
of infection, by virus isolation in mammalian cell culture or RT-PCR, or (ii) as indirect 
detection of specific IgM and IgG antibodies with serological methods as enzyme im-
munoassay, immunofluorescence assay or neutralization test.  
As the majority of patients come for medical attention when neurological symptoms are 
manifest, it is the current experts’ opinion that virus isolation and RT-PCR at this time are of 
minor importance for the diagnosis of TBE, because at the beginning of the second phase of 
illness the virus itself is only rarely detectable in blood and CSF. Therefore, the diagnosis of 
TBE is mainly done by serological methods, usually enzyme-linked immunosorbent assay 
(ELISA) based on purified virions or recombinant virus-like particles, which have been 
developed towards higher specificity and sensitivity in the last decade (Holzmann, 2003; 
Sonnenberg et al., 2004; Günther and Haglund, 2005; Ludolfs et al., 2009).  
However, detection by PCR methods could be valuable for an early differential diagnosis of 
TBE (Saksida et al., 2005; Schultze et al., 2007). This is particularly true for patients living in 
or coming from areas where more than one tick-transmitted disease is endemic. Detection of 
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specific nucleic acid from blood and CSF depends on the sampling at the right time. The 
highest yield of TBE virus specific RNA is obtained during the transient viremia in the first 
week of the disease, much less in the second week after the appearance of antibodies and 
only occasionally later on (Holzmann, 2003; Puchhammer-Stöckl et al., 1995).   
The benefit of molecular detection methods depends on the attention that affected people 
and clinicians pay to tick bites and symptoms. The earlier a correct diagnosis is obtained 
(e.g. TBE or other etiology), the earlier an appropriate therapy can be introduced. This could 
have dramatic influence upon survival and outcome of a suspected CNS disease.  
RT-PCR can also be of great diagnostic help when the patient has not developed antibodies 
at the beginning of the second phase, has a severe case of TBE or has died after a relatively 
short course of infection (Gelpi et al., 2005; Schwaiger and Cassinotti, 2003).  
Both serological and molecular detection methods for TBE are useful as single applications 
or in combination for clinical diagnosis, immunity testing, epidemiological surveillance and 
survey of virus prevalence in ticks and vertebrate hosts.  
Although ELISA is currently the method of choice, due to its simple performance and ease 
of automation, and new commercial serological assays have been developed with higher 
sensitivity and specificity, certain restrictions have to be taken into consideration for the 
application of serological methods (Table 1).   
 
Method Serology RT-PCR 
Advantages 
-Allows reliable detection of 
IgM and IgG antibodies in 
serum and CSF up from the 
2nd week of disease 
- Allows early diagnosis 
by detection of TBE virus 
specific RNA in the first 
phase of infection, if 
patient is hospitalized at 
this time point 
 
- High throughput of clinical 
specimens is possible 
- Provides opportunity to 
discriminate between 
TBE virus subtypes 
 
- Commercial kits are 
available  
- Provides opportunity to 
quantify viral load  
Disadvantages 
- Cross-reactions with 




- Neutralization test has a 
high specificity, but requires 
higher containment 
laboratory  
- Requires trained 
laboratory personnel for 
proper handling 
Table 1. Advantages and disadvantages of serology and RT-PCR for the diagnosis of TBE 
(modified from Donoso Mantke et al., 2007a) 
An early diagnosis by detecting only IgM is questionable, since IgM antibodies can persist 
for up to 10 months in vaccinees or individuals who acquired the infection naturally. 
Therefore, confirmation by detection of specific IgG is recommended, but may turn out 





1–2 weeks later is rarely done. Moreover, a major problem when using ELISA and 
immunofluorescence assays lays in the high cross-reactivity of the flaviviral antigenic 
structure. Possible diagnostic difficulties may arise due to cross-reactions of antibodies 
elicited by other flavivirus infections or vaccinations. This could happen in areas where 
other flaviviruses co-circulate (e.g. West Nile virus in the southern parts of the TBE endemic 
area), in patients recently returned from areas endemic for other flaviviruses (e.g. dengue 
virus endemic areas) or in individuals being vaccinated against TBE virus, Japanese 
encephalitis or yellow fever virus (Holzmann, 2003; Niedrig et al., 2001).   
Thus, verification of positive results by neutralization test is advised which, due to the use 
of infectious virus particles, requires the handling in higher containment laboratories which 
makes this test time-consuming and expensive.  
As mentioned, the molecular diagnostics for TBE are restricted to the first (viremic) phase of 
infection. But, in combination with a higher awareness of the disease, this fact could be more 
an advantage than an obstacle, leading to an early diagnosis of TBE (Table 1).  
Also, the RT-PCR provides the opportunity to discriminate between all subtypes of TBE. 
This could be an important aspect while facing co-circulation of the different subtypes in 
some European regions (Růžek et al., 2007; Achazi et al., 2011). Unfortunately, a negative 
PCR result in serum or CSF of a patient is not predictive for the absence of a TBE infection. 
This may be caused either by the short viremia of the infection, by sampling at inap-
propriate times and/or by improper handling of diagnostic specimens. The lack of 
commercial assays of standardized quality provides another reason why RT-PCR has not 
been established so far in microbiological laboratories for TBE diagnosis (Donoso Mantke et 
al., 2007a). The presence of many in-house assays especially for the molecular detection of TBE 
requires quality control studies in order to avoid false positive and/or negative results and to 
achieve the same diagnostic quality among the different assays (Donoso Mantke et al., 2007b).  
8. Prevention and treatment 
Besides general preventive measures, like wearing appropriate clothing or checking the skin 
for attached ticks, TBE can be successfully prevented by active immunization (Kunz, 2003; 
Heinz et al., 2007).  
In Russia, several vaccines are produced by using Far Eastern TBE subtype viruses: e.g. the 
vaccine of the Institute of Poliomyelitis and Viral Encephalitis (IPVE), in Moscow with strain 
Sofjin, and EnceVir by Virion, in Tomsk with strain 205.  
In Europe two vaccines are available which are based on European TBE virus strains: FSME-
IMMUN by Baxter Bioscience, Orth an der Donau, Austria with strain Neudoerfl, and 
Encepur by Novartis Vaccines and Diagnostics, Marburg, Germany with strain K23.   
The large envelope protein E induces the production of neutralizing antibodies important 
for the protective immunity. Due to the highly conserved structure of this antigen broad 
cross-protection by the vaccines could be shown against TBE viruses of all three subtypes 
(Ecker et al., 1999; Leonova and Maistrovskaya, 1996; Klockmann et al., 1991; Holzmann et 
al., 1992; Hayasaka et al., 2001).  
Since their introduction both European vaccines have undergone several modifications and 
are manufactured by the same steps during the production process (Rendi-Wagner, 2008). 
Viral antigens are propagated in chick embryo cells, filtered and inactivated by 
formaldehyde, and purified by ultracentrifugation. During the formulation the antigens are 
adsorbed to aluminium hydroxide and stabilized with human albumin (FSME-IMMUN) or 
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sucrose (Encepur). Thiomersal was removed from both vaccine formulations in the 1990s to 
fulfill high safety and tolerability standards (Barrett et al., 2003).  
The conventional immunization schedules for primary immunization are similar for both 
vaccines, with three intramuscular doses given on 0, 21 days–3 months and 9–12 months. 
Thus, both vaccines induce antibody concentrations that are believed to be protective in 
over 90% of children and adults (Lindquist and Vapalathi, 2008). Due to the high homology 
of the antigens and demonstrated cross-boostering in clinical studies, the two TBE vaccines 
seem interchangeable after a complete primary immunization (Rendi-Wagner et al., 2004; 
Bröker and Schöndorf, 2006). So far, the protective amount of antibodies is not clearly 
defined and standardized for both vaccines. Also, occasional vaccine breakthroughs have 
been reported (Bender et al., 2004; Kleiter et al., 2007; Andersson et al., 2010).  
Besides vaccines for adults, both European vaccine manufacturers offer pediatric vaccine 
formulations containing half the dose of viral antigen of the adult ones to improve 
tolerability in children (Zent et al., 2003; Pavlova et al., 2003; Pöllabauer et al., 2010).   
An age-dependent immune response after vaccination could be shown, with children having 
an enhanced response in comparison to adults (Girgsdies et al., 1996), whereas especially 
vaccinees aged over 60 years frequently have a poor antibody response (Hainz et al., 2005).  
Data regarding the persistence of post-immunization antibodies led the manufacturers to 
change their recommendations (Rendi-Wagner, 2008). Regular boosters are recommended 
every 5 years for age-groups ≤ 49 years of age (except for the first booster after 3 years). In 
age-groups > 49 years of age a 3-year-booster interval is recommended due to the 
significantly gradual decline of post-immunization antibodies.    
Rapid immunization schedules have been introduced by both vaccine producers for people 
who require immunity at short notice, such as travelers travelling to TBE-endemic areas or 
when the tick season has already started. However, since the experience with TBE vaccines 
is mainly based on the conventional immunization schedules, these should be always ap-
plied wherever possible.  
In Russia, IPVE vaccine is applied for adults and children of three years and over, the 
vaccine is given in two doses over 5–7 months with the revaccination after 1 year, and then 
every 3 years. EnceVir vaccine is administered to adults aged 18 years and more, the vaccine 
is also given in two doses over 5–7 months, with the revaccination after 1 year and every 3 
years thereafter. This vaccine is also available for the rapid immunization schedule: two 
doses over 1–2 months.   
Clinical therapy is only symptomatic with strict bed rest, usually in an intensive care unit, 
until the fever and neurological symptoms have subsided. Maintenance of water and 
electrolyte balances, sufficient caloric intake, and administration of analgesics, vitamins, and 
antipyretics are the central pillars of clinical treatment of TBE patients.  
Since there is no specific treatment for TBE available to date, and the administration of 
hyperimmunoglobulin for a passive post-exposure prophylaxis is highly questionable 
concerning the virtue and not recommended anymore due to concerns about antibody-
dependent enhancement of infection (Kaiser, 1999; Waldvogel et al., 1996; Jones et al., 2007), 
active immunization should always be recommended for people living in or travelling to 
TBE endemic areas. 
9. Future trends 
Since the first descriptions of TBE and its viral etiology in the 1930s/1940s the scientific 





the structure and molecular biology of TBE virus and the biotic and non-biotic factors 
underlying its natural cycle. Also, there are effective and safe purified inactivated vaccines 
available on the market, which made vaccination an extremely successful measure for 
preventing the disease.  
However, there are several issues in the context of TBE which need to be deepened in the 
future, like:  
1. Further development of rapid differential diagnosis of TBE virus in combination with 
other tick-borne pathogens by detecting both the nucleic acids and viral antigens. 
2. Further efforts in identifying the genetic basis of TBE virulence.  
3. Study of interaction of virus and immune cells for further prognosis of clinical course 
and outcome of TBE and, if possible, for better treatment.   
4. Establishment of international databases for TBE virus: epidemic risks, individual risks, 
mapping and characterization of natural foci, circulating genotypes, circulation of other 
tick-borne pathogens in TBE foci.   
5. The taxonomic position of Louping ill virus (and subtypes Turkish sheep-, Spanish 
sheep encephalitis virus) and Greek goat encephalitis virus is under consideration.  
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